The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer.

Sci Rep · 2017 · PMC5227705 · PMID 28079142

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Third, patients had a median survival of 24.5 months (95% CI 20.524 to 28.476) for the del19 group compared with 21.6 months (95% CI 7.620 to 35.580) for the L858R group, and these data showed a trend.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.